Last reviewed 2026-04-23 · How we verify

TAR-210

TAR-210 is a bispecific antibody targeting the PD-1 and LAG-3 immune checkpoint proteins.

TAR-210 is a bispecific antibody targeting the PD-1 and LAG-3 immune checkpoint proteins. Used for Metastatic non-small cell lung cancer, PD-L1 positive.

At a glance

Mechanism of action

By binding to PD-1 and LAG-3, TAR-210 aims to restore and enhance the body's immune response against cancer cells. This is achieved by blocking the inhibitory signals sent by PD-1 and LAG-3, allowing the immune system to attack and destroy cancer cells more effectively.

Approved indications

• Metastatic non-small cell lung cancer, PD-L1 positive

Common side effects

• Fatigue
• Nausea
• Diarrhea
• Vomiting
• Anemia
• Thrombocytopenia
• Neutropenia
• Leukopenia
• Anorexia
• Weight loss

Key clinical trials

• Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer (PHASE1, PHASE2)
• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (PHASE3)
• A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (PHASE1)
• A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TAR-210 CI brief — competitive landscape report
• TAR-210 updates RSS · CI watch RSS
• Janssen Research & Development, LLC portfolio CI